AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02112019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: saline
Study NCT02112019 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: hydrocortisone
Study NCT01784276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Video peer modeling: The video demonstrates various stages of the dental visit experience. Children assigned to intervention Groups B or D reviewed the video at least once, but as many times as possible before the follow up visit.~Video goggles: This is a sunglass style video eyewear that contains two computer screens that can be used to watch 2 or 3D movies. Subjects randomized to Group C or D watched a 2D movie during the return visit, using the video goggles. Subjects who refused or were unable to wear the goggles watched the movie using a hand held portable DVD player.
Study NCT02290847 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy (cognitive only version; CPT-C)
Description: CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions (Resick, Monson, \& Chard, 2008; Resick \& Schnicke, 1993). CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
Study NCT02797509 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychosocial Skills-Based Intervention
Description: Subjects will attend group skills-based sessions once weekly (either in-person or via Vidyo) for 6 weeks and learn skills to cope and manage stroke-related stressors.
Study NCT01028677 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: nasal spray without oxytocin
Description: 6 insufflations of nasal spray without oxytocin (0.1 metered dose/insufflation) twice daily for 6 weeks
Study NCT02889185 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RTX1 IMAGIN EYE retinal camera
Description: In addition to the routine examination including OCT, an imaging using RTX1 IMAGIN EYE retinal camera will be performed.
Study NCT02744183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Moderate intensity exercise
Study NCT02744183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: Moderate intensity exercise
Study NCT02744183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Breakfast
Description: Breakfast consumption
Study NCT02744183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maintain habitual habits
Description: Normal physical activity and dietary behaviors maintained
Study NCT03778866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bicarbonate-buffered handling medium
Description: The investigators will evaluate whether the usual bicarbonate culture medium can replace the HEPES buffered medium effectively.
Study NCT00948922 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bortezomib
Description: AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m\^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m\^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).
Study NCT00948922 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Melphalan
Description: AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m\^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m\^2/day IV over 30 minutes.
Study NCT00948922 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Autologous Stem Cell Transplant
Description: Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Stem cell mobilization with granulocyte colony-stimulating factor (GCSF) at a dose of 10 μg/kg/day as per institutional standards. CD34+ peripheral blood stem cells will be collected following the administration of G-CSF as per institutional standards. Day 0 Infusion of autologous stem cells.
Study NCT00948922 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fludarabine
Description: Days -6,-5,-4,-3 Fludarabine 30 mg/m\^2/day IV
Study NCT00948922 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Allogeneic Stem Cell Transplant
Description: Allogeneic Stem Cell Transplant: Allogeneic Peripheral Blood Stem Cell Rescue. Day 0 Infusion of allogeneic peripheral blood stem cells. For the allogeneic matched-related donors peripheral blood stem cells will be harvested with GCSF mobilization and infused fresh to the recipients. Allogeneic donor stem cells may also be cryopreserved if they cannot be infused fresh.
Study NCT01146015 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trivalent influenza subunit vaccine Influvac
Description: 3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
Study NCT00888797 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol and Etodolac
Description: Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
Study NCT00888797 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol and Etodolac
Description: Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
Study NCT05969587 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: 5% cysteamine cream
Description: 5% cysteamine cream (Cyspera®) was acquired from Scientis APAC Pte. Ltd. (Singapore, Singapore).Subjects were instructed to thinly apply the designated creams to their whole face every evening 15 minutes after cleansing their faces with a designated soap and the application of a skin moisturizer. The cysteamine cream was washed off 15 minutes after application
Study NCT05969587 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: hydroquinone cream group
Description: 4% w/w hydroquinone cream (Melquine™) and 0.06% w/w betamethasone valerate cream (Rinderon®-V; equivalent to 0.05% betamethasone) were acquired from Sinphar Pharmaceutical Co., Ltd. (Yilan, Taiwan). Subjects were instructed to thinly apply the designated creams to their whole face every evening 15 minutes after cleansing their faces with a designated soap and the application of a skin moisturizer. Subjects in the hydroquinone cream group were told to apply a 2:1 ratio of the hydroquinone and betamethasone creams. The hydroquinone/betamethasone creams were left on the skin until the following morning.
Study NCT04755894 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HDDO-1756
Description: single dose
Study NCT04755894 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HDDO-17561/HDDO-17562
Description: single dose
Study NCT03183843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran Etexilate
Description: Dabigatran Etexilate 150 mg capsules for oral administration twice a day
Study NCT03183843 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin 2.5 mg tablets for oral administration once a day
Study NCT03475758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin
Description: adding goserelin with chemotherapy
Study NCT00156091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: 5- 20 mg QD
Study NCT00156091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asenapine
Description: 5 or 10 mg BID
Study NCT00156091 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Placebo
Study NCT03139136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MBS2320
Description: As described in the arm descriptions
Study NCT03139136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As described in the arm descriptions
Study NCT06212284 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Citalopram 20mg
Description: Doses were delivered in gelatine capsules filled with microcrystalline cellulose.
Study NCT06212284 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Doses were gelatine capsules filled with microcrystalline cellulose
Study NCT01462656 — intervention group
Intervention type: DRUG
Intervention: Non-EZG containing AED polytherapy
Description: AED polytherapy without EZG
Study NCT01462656 — intervention group
Intervention type: DRUG
Intervention: EZG containing AED polytherapy
Description: AED polytherapy including EZG
Study NCT01462656 — intervention group
Intervention type: DRUG
Intervention: Non-EZG AED monotherapy
Description: AED monotherapy without EZG
Study NCT01462656 — intervention group
Intervention type: DRUG
Intervention: EZG AED monotherapy
Description: Any off-label use of EZG as monotherapy
Study NCT00860080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL01
Description: PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
Study NCT00860080 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
Study NCT00587795 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: StabilAir Wrist Brace
Description: Patient will be placed in a StabilAir Wrist Brace 10-14 days after initial injury and return for follow up visits at 6 weeks; 3, 6, 12 and 24 months.
Study NCT00587795 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placement of sugar tong splint or plaster cast
Description: Patients will receive a sugar tong splint or plaster cast for their wrist fracture. They will return for x-rays and an exam at 6 weeks; 3, 6, 12 and 24 months.
Study NCT02347735 — intervention group
Intervention type: OTHER
Intervention: No interventions, only data collection
Description: Only data is collected from the subjects in both groups.
Study NCT00783666 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
Description: Lactic Acid
Study NCT03041766 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sm14
Description: Three 0.5 mL intra-muscular injections of the vaccine solution (50µg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
Study NCT03041766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLA-SE solution
Description: Two (2) adjuvant concentrations will be made and packaged at 0.4 mL/vial, per GMP standards. One lot at the concentration of 10µg/mL for injection in the first cohort at 2.5µg GLA-SE/injection and one lot at the concentration of 20µg/mL for the second cohort intended to receive 5.0µg of GLA-SE/injection
Study NCT01023425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: donepezil
Description: from 5mg to 10mg, once a day, 12 months
Study NCT01951573 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Delefilcon A multifocal contact lenses
Description: Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use
Study NCT01951573 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Lotrafilcon B multifocal contact lenses
Description: Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement
Study NCT00700024 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Testim
Description: 50 mg/dose7day
Study NCT00700024 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength training
Description: three times a week
Study NCT00700024 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo
Study NCT00777829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: zolpidem
Description: Participants will receive one dose of 10 mg before each nap.
Study NCT00777829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zolpidem
Description: Participants will receive one dose of 10 mg before each nap.
Study NCT00777829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive a dose of placebo before each nap.
Study NCT00777829 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participants will receive a dose of placebo before each nap.
Study NCT04502875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRP
Description: Platelet Rich Plasma (PRP) is an autologous blood component derivate from the own patient blood, with a high concentration in platelets. The liquid fraction obtained after the soft centrifugation of Whole Blood (WB) collected with anticoagulant, in a way that most of the red cells and leukocytes are sedimented and removed, but most of the platelets are kept in the supernatant plasma. The platelet concentration in PRP is not well defined.
Study NCT04502875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PPP
Description: PPP is the liquid fraction obtained after the hard centrifugation of WB collected with any anticoagulant. PPP does not contain cells. (Hematocrit lower than 1% and leukocytes below 1 x 109/L) x but contains WB proteins (including clotting factors), ions, microelements and water. PPP can be also being collected using an apheresis technique.
Study NCT00027807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion.
Study NCT00027807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: GM-CSF Injections will be given SQ GM-CSF (250 μg/m2/twice weekly), to start 3 days before the first ATC infusion and ending 1 week after the last ATC infusion.
Study NCT00027807 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: The time for armed-ATC infusions will vary from patient to patient, but the dose of armed-ATC (up to 40 billion) will be given over 30 min.
Study NCT01059500 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Webtool
Description: Webtool provides the numeric PTP estimate for ACS and PE, and one of three testing recommendations. For ACS, PTP \<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5 to 5.5%: obtain a troponin I measurement at presentation and 120 minutes later, and if both are normal, no further testing; PTP >5.5%: proceed to provocative testing. For PE, PTP\<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5-10%, obtain a quantitative D-dimer and if normal, no further testing. PTP 10-20%, proceed directly to pulmonary vascular imaging, and if PTP>20% consider empiric anticoagulation with heparin if no contraindications.
Study NCT04116008 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Pain Followup and Monitorization
Description: Numeric Rating Scale (NRS) pain score will be recorded from recovery room followed by 2.-4.-6.-12.-24.hours. Intravenous meperidine administration at 0.5 mg / kg rescue analgesia was determined in patients with a NSR score of 4 and over in the postoperative collection room. It is planned that the patient will continue to follow the hourly NRS score in ward. Intramuscular diclofenac will be administered in this period if NRS 4 and if it is over, intravenous 0.5 mg / kg meperidine will be administered if NRS score is 4 or more after 2 hours. Salvage analgesic needs and times will be noted in detail, and the use of rescue analgesics, as well as NRS scores at designated hours, will be kept in a statistical evaluation.
Study NCT03162068 — intervention group
Intervention type: OTHER
Intervention: Osteodensitometry and pQCT
Description: The peripheral Quantitative Computed analyses the bone architecture with distinction between cortical and trabecular compartment. We aim to determine the specificity of osteoporosis induced by glucocorticoids excess in comparison to post menopausal osteoporosis thanks to pQCT analysis.
Study NCT01080092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: breathing technique
Description: breathing technique as a stress management technique, reinforced by biofeedback
Study NCT00737503 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotavirus Vaccine (ROTARIX)
Description: Rotavirus Vaccine two doses four weeks apart
Study NCT01661205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ablation procedure staged catheter ablation
Description: AtriCure Bipolar System used in conjunction with a catheter ablation procedure performed 1-10 days apart
Study NCT04358718 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: general anesthesia
Description: Patients will receive intraoperative and postoperative intravenous opioid-based analgesia for robot-assisted laparoscopic radical cystectomy.
Study NCT04358718 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: general anesthesia combined with epidural analgesia
Description: Patients will receive epidural ropivacaine-based analgesia for robot-assisted laparoscopic radical cystectomy.
Study NCT02963948 — intervention group
Intervention type: BEHAVIORAL
Intervention: Meetings with implementation leader(s)
Description: The perceived appropriateness of the intervention to medical staff will affect an intervention's initial adoption as well as sustainability. We will assess this through focus groups with staff, conducted approximately 1-2 months after implementation of the screening and CDS tools.
Study NCT01080092 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: behavioral strategies
Description: the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
Study NCT00806208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-507
Description: 0.012 mg/kg MEDI 507 and Methylprednisolone
Study NCT00806208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-507
Description: 0.04 mg/kg MEDI 507 and Methylprednisolone
Study NCT00806208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-507
Description: 0.12 mg/kg MEDI 507 and Methylprednisolone
Study NCT00806208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MEDI-507
Description: 0.4 mg/kg MEDI 507 and Methylprednisolone
Study NCT00806208 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV (alternative) study days 0, 3,6, and 9
Study NCT04168255 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Double tamponade
Description: Double tamponade procedure in retinal detachment with PVR and inferior breaks
Study NCT00070564 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: pegfilgrastim
Description: Given IV
Study NCT00070564 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pegfilgrastim
Description: Given IV
Study NCT00070564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AC regimen
Description: Given IV
Study NCT00070564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC regimen
Description: Given IV
Study NCT00070564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV
Study NCT00070564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV
Study NCT00070564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00070564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT00070564 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel
Description: Given IV
Study NCT00070564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT02044003 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Innovasc Tack Intravascular Staple System (Tack)
Description: Tack-It Dissection repair
Study NCT00624689 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Modified formula (MFGM-enriched formula with reduced energy and protein content)
Description: MFGM-enriched formula with reduced energy and protein content
Study NCT03077607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib
Description: Arm A: 0.5 mg oral dose Arm B: 1 mg oral dose
Study NCT03077607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: 100 mg oral dose
Study NCT03077607 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampin
Description: 600 mg oral dose
Study NCT02455453 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-FFNP
Study NCT02455453 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CTI/Siemens Biograph 40 PET/CT Scanner
Description: * Will include (1) 18-FDG-PET/CT scan~* Will include (2) 18F-FFNP-PET/CT scans